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CARS = compensatory anti-inflammatory response syndrome; G-CSF = granulocyte colony stimulating factor; ICU = intensive care unit; IVIG =
intravenous immunoglobulin; IL = interleukin; IFN = interferon; TNF = tumour necrosis factor.
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Introduction
An infection that is not present or incubating when a patient
is admitted to hospital but is detected 48–72 hours after
admission is considered to a nosocomial rather than
community-acquired infection [1]. Nosocomial infections
affect about 30% of patients in intensive care units (ICUs;
incidence rates range between 9% and 37%, depending on
the population studied and the definition used) [2]. Patients
with severe brain injury appear to be at greater risk for
nosocomial infections than other ICU patients. In one study
[3], 41 out of 82 (50%) patients with severe head injury
experienced at least one infectious complication during their
hospitalization. Piek and coworkers [4] examined 734
patients with severe head trauma and identified pulmonary
infections in 41% and septicaemia in 10% of patients.
Fassbender and colleagues found that 1 week after
admission to hospital 27% of 52 patients with ischaemic
stroke fulfilled criteria for hospital-acquired infection [5].
Hilker and coworkers [6] prospectively evaluated 124
patients with acute stroke who were treated at a neurological
ICU. In that study the incidence of stroke-associated
pneumonia was 21%. Berrouane and colleagues [7] found
higher incidence rates of early-onset pneumonia in patients
with neurotrauma than in patients without neurotrauma
hospitalized in a neurosurgical ICU (20.1/1000 versus
15.7/1000 patient days and 34.2/1000 versus 27.9/100
ventilation days). Ventilator-associated pneumonia is among
the most important subtypes of nosocomial infections, and
the incidence of this type of pneumonia in brain-injured
patients ranges from 28% to 40% [8].
Development of nosocomial infection depends on two key
factors: decreased host defences and colonization by
pathogenic micro-organisms. Here, we review the significance
of immune status in development of nosocomial infections in
brain-injured patients. Mechanical causes of immuno-
depression (e.g. intubation and invasive procedures) are not
discussed here. Data for the review were identified by
searches of the Medline database, the Cochrane Library and
references from relevant articles (January 1980 to June
2003). Search terms included the following: ‘head trauma’,
‘brain injury’, ‘infection’, ‘immunity’ and ‘intensive care’.
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Abstract
Of brain-injured patients admitted to intensive care units, a significant number acquires nosocomial
infections. Increased susceptibility to infectious agents could, at least partly, be due to transient
immunodepression triggered by brain damage. Immune deficiency in patients with severe brain injury
primarily involves T cell dysfunction. However, humoral and phagocytic deficiencies are also
detectable. Activation of the hypothalamo–pituitary–adrenal axis and the sympathetic nervous system
plays a crucial role in brain-mediated immunodepression. In this review we discuss the role of
immunodepression in the development of nosocomial infections and clinical trials on
immunomodulation in brain-injured patients with hospital-acquired infections.
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Why are infections so frequent in brain-injured
patients – is ‘immunoparalysis’ involved?
Immune deterioration has been reported in patients after
trauma, surgery, or blood loss (for review [9,10]). Alterations
in host defence mechanisms after trauma that are potentially
important to development of infectious complications include
the following: paralysis of monocyte function (transient
nonreactivity of monocytes toward stimulation with endotoxin,
depression of antigen presentation capacity, and enhanced
secretion of the anti-inflammatory cytokine IL-10); suppression
of T cell functions (decreased response to mitogenic
activation and decreased IL-2 production); and impairment of
B-cell function (decreased capacity to produce antibodies).
The high frequency of infection in brain-injured patients
suggests that host defences may be compromised after
severe brain trauma, even in the absence of clinically
important systemic injury. In the early 1990s several groups
showed independently that severe brain injury precipitates
significant deficiencies in the immune system, and this finding
was confirmed and later extended by other researchers.
Immunological abnormalities that are found in patients with
brain injury are summarized in Table 1 [11–21].
The cellular arm of immunity is the most affected, although
phagocytic and humoral deficiencies are also detectable.
Defects in cellular immunity include reduced number of
circulating T cells, increased proportion of suppressor cells,
depressed mitogen-induced proliferative response, and
depressed delayed-type hypersensitivity reaction [11–16].
Moreover, it has been postulated that monocytes could be
target cells in brain-mediated immunosuppression; monocyte
deactivation, with decreased capacity for antigen presentation
and depressed secretion of proinflammatory cytokines,
increased the risk for infectious complications [21].
Immunodeficiencies are noted soon after brain injury; for
example, T-cell anergy is seen within several hours after
brain damage [12]. These deficiencies are most prominent
during the first few days after brain injury [14,17] and
precede the infectious complications, which reach a peak
incidence at 5–11 days after brain trauma [4]. The immuno-
depression in brain-injured patients appears to be a
transient phenomenon. Recovery of T-cell function was
observed 3 months after head injury [14]. In patients with a
vegetative state, all neutrophil functions (superoxide
release, migration and chemotactic capability) were found
to be normal when measured several months after the brain
damage [18]. Further studies are needed to determine how
the immune system recovers after brain damage and to
compare the recovery process between brain-injured and
other ICU patients.
The mechanisms that lead to immunological defects in
patients with head trauma or severe stroke are still poorly
understood. In many cases immune deficiencies (defect in
cellular immunity, monocyte deactivation) closely resemble
those observed in patients after ‘non-neurological’ trauma,
surgical injury, or blood loss [10]. Generally, local infection or
sterile trauma induces a local inflammatory response, with
release of proinflammatory mediators (tumour necrosis factor
[TNF]-α, IL-1β, IL-6). Overwhelming immune activation can
result in systemic inflammatory response syndrome and septic
shock. To control the potentially harmful proinflammatory
response, the immune system releases several anti-
inflammatory mediators (IL-10, IL-1 receptor antagonist,
soluble TNF-α receptor), causing compensatory anti-
inflammatory response syndrome (CARS). Monocyte
deactivation with decreased capacity for antigen presentation
and depressed secretion of proinflammatory cytokines
appear to be critical events in CARS.
Table 1
Immunological defects in brain-injured patients
Defect Examples
T cells Reduced number of total circulating T cells, T-helper cells, T-suppressor cells, natural killer cells and IL-2 
receptor-bearing cells [11–15]
Disproportionate high percentage of T cells of the CD4+/CD45+ (suppressor/inducer) phenotype relative to the 
percentage of T cells of the CD4+/CDw29+ (helper/inducer) phenotype [16]
Reduction in the proliferative response of T cells to mitogen stimulation [11–14]
Decreased IFN-γ and IL-2 production [13,17]
Anergy to delayed-type hypersensitivity skin testing [11–13]
Depression in lymphokine-activated killer cell cytotoxicity [13,17]
B cells [14,15] Reduction in IgG and IgM
Reduction in components of complement system (C1q, C2, properdin)
Neutrophils [15,18] Decrease in superoxide generation
Monocytes [19–21] Increased IL-6 and IL-10 production
IFN, interferon; IL, interleukin.268
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Cerebral insults can also cause a brain-mediated systemic
anti-inflammatory syndrome [22]. Brain cytokines triggered by
trauma, ischaemia, or haemorrhage can activate CARS, even
in the absence of preceding systemic inflammation. Both
locally produced cytokines in the brain and direct brain-stem
irritation can trigger strong sympathetic activation and
stimulation of the hypothalamo–pituitary–adrenocortical axis
[22]. Glucocorticoids possess anti-inflammatory and
immunosuppressive properties. They inhibit synthesis of
proinflammatory cytokines (IL-1, TNF-α), and can augment
the secretion of the anti-inflammatory cytokine IL-10 [23]. In
addition, glucocorticoids suppress expression of major
histocompatibility complex class II molecules on antigen-
presenting cells and can inhibit various lymphocyte functions.
Catecholamines inhibit TNF-α production by monocytes and
increase IL-10 release [24,25].
It should be also kept in mind that some drugs used in the
ICU can impair immune responses. These include gluco-
corticoids, catecholamines, benzodiazepines [26], midazolam
and propofol [27]. On the other hand, the histamine-2
receptor antagonist ranitidine can modulate immune
response by increasing interferon (IFN)-γ production by
lymphocytes [28].
Can we effectively prevent and treat nosocomial
infections in brain-injured patients – is there a
role for immunomodulatory therapy?
Various immunomodulatory agents, including IFN-γ, granulocyte
colony-stimulating factor (G-CSF), granulocyte–macrophage
colony-stimulating factor and immunoglobulins, have been
used in ICU patients to prevent or treat nosocomial infections
by activating the immune system. Here we discuss the results
of studies focused on brain-injured patients.
G-CSF promotes the differentiation and proliferation of
neutrophil precursor cell, prolongs the survival of neutrophils,
and acts as a chemoattractant for granulocytes. In a
randomized, placebo-controlled, double-blind, multicentre
phase II study [29], 40 patients with head trauma were given
one or two daily doses of recombinant human G-CSF
(filgrastim) for up to 10 days after hospitalization. The primary
study end-points were an increase in absolute neutrophil
count; frequencies of nosocomial pneumonia, urinary tract
infection and primary bacteraemia; and safety of G-CSF.
Secondary end-points were serum G-CSF level; duration of
hospitalization, antibiotic use and ICU stay; and 28-day
survival. Filgrastim caused a dose-dependent increase in
absolute neutrophil count. There was no difference in
pneumonia and urinary tract infections between groups. The
incidence of hospital-acquired bacteraemia was significantly
reduced in patients treated with high-dose G-CSF
(300 µg/day) compared with those treated with placebo
(0/19 [0%] versus 5/17 [29%]). There was no difference
between groups in any of the secondary end-points. That
study did not address the issue of the possible deleterious
effects of G-CSF on the injured brain [30], although this drug
appears to be safe for extracerebral complications [31].
In another study [32], administration of recombinant human
G-CSF ameliorated life-threatening infections without causing
lung injury or brain swelling in patients with severe head
injuries who were treated with a combination of high-dose
barbiturates and mild hypothermia. In that study eight patients
with head trauma received recombinant human G-CSF for
5 days, and the results of treatment were compared with
those in 22 patients who were not administered recombinant
human G-CSF. In patients treated with recombinant human
G-CSF, total leucocyte count, nucleated cell count and
neutrophil function increased significantly, whereas levels of
C-reactive protein and IL-6 decreased. Seven out of eight
patients treated with recombinant human G-CSF recovered
from life-threatening infections, and none of the eight patients
died. In contrast, in patients who did not receive recombinant
human G-CSF, infections continued after 5 days in 17 out of
22 patients, seven of whom died from severe infections
during hospitalization.
Intravenous immunoglobulin (IVIG) can modulate the immune
response in several ways, including by Fcγ receptor mediated
immunomodulation, by its impact on the idiotype/anti-idiotype
network, and by elimination of immunostimulating microbial
products (e.g. toxins, superantigens) [33]. An analysis of
randomized trials conducted by the Cochran Infectious
Diseases Group showed that polyclonal IVIG significantly
reduced mortality in sepsis and septic shock [34]. Gooding
and coworkers [35] conducted a randomized, double-blind
trial to determine whether IVIG decreases the incidence of
secondary infections in head-injured children. Eighteen
children with severe head injury received IVIG (400 mg/kg)
and 14 received albumin placebo within 48 hours after
admission. Unfortunately, no significant differences in the
incidence of pneumonia or in any other type of infection were
noted. In addition, there were no differences between groups
in the number of days on mechanical ventilation and in the
number of hospital days.
The available literature suggests that, in trauma and peri-
operative patients, immunonutrition may reduce the number
of infectious complications (for review [36]). Enhancing
immunity through diet is generally done by adding n-3 fatty
acids, arginine and nucleotides to an otherwise nutritionally
complete formula. Most trials have unfortunately failed to
demonstrate any benefit of such interventions in terms of
important outcomes such as mortality [36].
Rapp and coworkers [37] reported the first prospective,
randomized trial to suggest that early administration of
parenteral nutrition can influence immune status in head-
injured patients. In that study patients were randomly
assigned to receive parenteral nutrition (20 patients) within
48 hours of admission or nasogastric tube feedings (18269
patients). After 18 days of hospitalization, eight out of 18
enteral nutrition patients died whereas no deaths occurred in
the patients receiving parenteral nutrition. Reactions to skin
test antigens were used throughout the study as a measure
of immunological function. Approximately 40% of patients
receiving parenteral nutrition exhibited positive skin test
reactions, as compared with 14% of patients receiving
enteral nutrition (P < 0.04).
In another study [38], nine patients with severe closed-head
injury were prospectively randomized either to early parenteral
nutrition (four patients) at day 1 or to delayed parenteral
nutrition (five patients) at day 5. Significant increases in total
CD4+ cell counts, a rise in the CD4+/CD8+ ratio and
improved lymphocyte responses after mitogen stimulation
were noted in patients receiving early nutrition as compared
with those receiving delayed parenteral nutrition.
The results of a systematic review assessing the significance
of nutritional support for head-injured patients suggested that
early feeding may be associated with a trend toward better
outcome in terms of survival and disability, but further studies
are needed [39].
Rixen and coworkers [28] demonstrated an immuno-
modulatory effect of the histamine-2 receptor antagonist
ranitidine, both at cellular and mediator levels, in patients after
severe head injury. In that randomized, prospective, double-
blind study, nine patients received continuous infusion of
ranitidine (6.25 mg/hour) for up to 5 days and 11 patients
received placebo. Treatment with ranitidine, but not with
placebo, was associated with a significant increase in CD4+
lymphocytes, increased IFN-γ production after mitogen
stimulation, and significant decrease in CD8+ lymphocytes.
The mortality rate was similar between groups; one patient
died in placebo group, and among those treated with
ranitidine no patients died.
Conclusion
Reports published to date on modulation of immune function
in brain-injured patients have several flaws. The number of
included patients was too small to draw firm conclusions.
Examined groups were heterogeneous with respect to
aetiology of brain injury (trauma, haemorrhage) and severity of
disease. Although T lymphocytes appear to be the most
affected in patients with brain injury, there is a lack of studies
attempting to modulate cell-mediated immunity in brain-
injured patients.
Several important issues should be addressed in future
studies. First, the mechanisms responsible the immuno-
depression in brain-injured patients (e.g. endocrinological and
stress-related mechanisms) require further exploration.
Second, future studies should be conducted in large groups
of carefully selected patients at high risk for infection. It is
important to select appropriate patients for immunotherapy.
Patients with severe brain injury are not good candidates for
immunotherapy because death in this group is usually not
directly related to infectious complications but rather is
caused by brain-stem damage. Therefore, in this group
potentially beneficial effects of immunotherapy can be
overwhelmed by the primary brain damage. Finally, the
specific cytokines or growth factors that have the greatest
therapeutic impact, and which are the patient populations
that will derive the greatest benefit remain to be defined.
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